Intestinal tight junction complex (TJC)

The intestinal tight junction complex (TJC) is the most apical component of the epithelial junctional complex, serving as the primary determinant of the intestinal paracellular barrier (PubMed: 27003731). It consists of transmembrane proteins, including claudins, occludin, and junctional adhesion molecules (JAMs), which interact with cytosolic scaffold proteins like zonula occludens (ZO-1, ZO-2, and ZO-3) to link the barrier to the actin cytoskeleton (PubMed: 23526606). Biologically, the TJC regulates the selective flux of ions and small molecules while restricting the passage of larger, potentially harmful luminal contents such as bacteria and dietary antigens (StatPearls: NBK554417). In pathological states like celiac disease and inflammatory bowel disease (IBD), the TJC is compromised, leading to increased intestinal permeability and chronic inflammation (PubMed: 31243154). Pharmacological targeting of the TJC involves agents like larazotide acetate, which inhibits the zonulin-mediated disassembly of tight junctions, thereby restoring barrier integrity (PubMed: 22564305). This complex represents a critical therapeutic target for managing diseases characterized by epithelial barrier dysfunction.

Other names

Zonula occludensParacellular barrierIntestinal epithelial barrierTight junction proteins

Modulation of paracellular permeability through the regulation of tight junction protein assembly and disassembly, often via antagonism of zonulin or inhibition of myosin light chain kinase (MLCK).